Permanent URI for this community
Browsing Pharmacy by Subject "Breast cancer, post-treatment pain, patient satisfaction with medication, pain, cancer, BPI, TSQM, , chemotherapy, hormonal therapy, biological therapy, side effects, convenience."
Now showing 1 - 1 of 1
Results Per Page
- ItemCANCER-RELATED POST-TREATMENT PAIN AND ITS IMPACT ON TREATMENT SATISFACTION WITH MEDICATION IN BREAST CANCER PATIENTS: A CROSS-SECTIONAL STUDY FROM PALESTINE(جامعة النجاح الوطنية, 2022-03-27) Daifallah, Aiman Hussein MohammedBackground: Pain after therapy is an important clinical problem in breast cancer patients. Unfortunately, patients with cancer have a lower quality of life due to undertreatment of post-treatment pain; therefore, improving medication management plans and palliative care became one of the most important targets of cancer therapy. Objectives: The current study aimed to examine the impact of posttreatment pain (pain severity and interference) on medication satisfaction in patients with various stages of breast cancer in Palestine. Methods: A correlational cross-sectional study was conducted at Al-Watani Hospital and An-Najah National University Hospital in the Nablus area. Using the Brief Pain Inventory (BPI), the intensity and interference of pain will be evaluated. Patients’ satisfaction with cancer management medications will be measured using the Treatment Satisfaction Questionnaire for Medication (TSQM). Results: Two hundred and fifty-four patients were included in this study. All were women, with a mean ± SD age of 53.1 ± 10.7 years. Patient satisfaction with medication reported was measured using the median scores of 4 domains (Effectiveness satisfaction 61.0 [50.0-72.2], Side effects satisfaction 59.4 [31.3-100.0], Convenience satisfaction 66.7 [61.1-77.8] and Global satisfaction 64.3 [50.0-78.6]). There were significant negative correlations (p < 0.05) between pain severity and effectiveness interference (r = -0.258, -0.319, respectively), side effects (r = -0.414, -0.514, respectively), convenience (r = -0.274, -0.307, respectively), and global satisfaction domain scores (r = -0.293, -0.287, respectively). The regression analysis results indicated an independent association between chemotherapy use and a higher global satisfaction score (p = 0.011). Also, lower pain interference score (p = 0.01) and patients without side effects (p = 0.47) were independently associated with higher Effectiveness satisfaction scores. Finally, lower pain interference scores (p < 0.001), patients without post-treatment pain (p = 0.034), and patients without side effects were independently associated with higher side effects satisfaction scores. There were significant positive correlations indicated between global satisfaction score and the use of cyclophosphamide (p =0.018), between effectiveness satisfaction score and the use of (p = 0.035), and between convenience satiasfaction score and the use of tamoxifen (p = 0.038). There were significant negative correlations between convenience satisfaction score and the use of adriamycin (p = 0.005), docetaxel (p = 0.008), capeciatabine (p = 0.022), gemcitabine (p = 0.026), and trastuzumab (p = 0.002). Conclusions: Patients with posttreatment pain, side effects, and greater pain interference with their functioning had lower satisfaction scores. Therefore, better management of their treatment medications, side effects, and pain medications is recommended to enhance their satisfaction and quality of life.